Publication
Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) showing a primary resistance (PRes) to NAs-based second line therapy after docetaxel (DOC): Preliminary results from a multic...
Orazio Caffo, Ugo De Giorgi, Gaetano Facchini, Lucia Fratino, Donatello Gasparro, Umberto Basso, Daniele Alesini, Marcello Tucci, Cinzia Ortega, Francesco Verderame, Giuseppe Procopio, Giovanni Lo Re, Enrico Campadelli, Claudia Omarini, Maddalena Donini, Franco Morelli, Paolo A. Zucali, Donata Sartori, Vincenza Conteduca, Enzo Galligioni
Journal of Clinical Oncology, March 2015, American Society of Clinical Oncology (ASCO)
DOI: 10.1200/jco.2015.33.7_suppl.216